Search results for "Cryoprecipitate"
showing 3 items of 3 documents
Pediatric non-red cell blood product transfusion practices: what's the evidence to guide transfusion of the ‘yellow’ blood products?
2020
Purpose of review Research studies pertaining to the management of pediatric non-red cell blood product transfusion is limited. Clinical practices vary within disciplines and regions. Anesthesiologists need evidence-based guidelines to make appropriate and safe decisions regarding transfusion of the 'yellow' blood products for pediatric patients. Recent findings This review outlines clinical indications for transfusion of fresh frozen plasma, cryoprecipitate, platelets, and fibrinogen concentrate in pediatrics. Recent studies of non-red blood cell transfusions in critical, but stable situations are highlighted. Recommendations to guide transfusion of the 'yellow' blood products in operative…
Evolving Risk Factors for Mortality after Lung Transplantation over the Last 10 Years: Insights from a Single-Centre Database
2016
s S233 218 (82%) patients received pooled platelet transfusion -median (IQR) 1(1-2) U. 209 (79%) and 129 (49%) patients received fresh frozen plasma (FFP) and cryoprecipitate with a median (IQR) of 3(2-4) and 0(0-0) U respectively. Conclusion: Rate and volume of transfusion of blood products compare favourably with centres performing surgery off CPB or on ECMO. Requirement for ECMO particularly for BTT, but also PGD is associated with high transfusion requirements.
Bleeding in Uremia
2021
Progressive deterioration of renal function eventually leads to uremia, which is associated with impaired function of platelets and a disturbed platelet–vessel wall interaction thus increasing the risk of bleeding in patients with renal failure. Furthermore, also anemia and anticoagulants/antiplatelet drugs contribute to the increased risk of bleeding in patients with end stage renal disease. Management of bleeding episodes in uremic patients includes an adequate dialysis, the correction of anemia with erythropoietin or erythropoetin stimulating agents, the administration of estrogens, desmopressin, fresh frozen plasma, cryoprecipitate, factor VIIa, or tranexamic acid. In severe bleeding ep…